Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging
Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging
复制标题
DOI：
10.1259/bjr.20150163
复制
发表时间：
2015-01-01
影响因子：
2.6
通讯作者：
Lee, J. H.
中科院分区：
文献类型：
--
作者：
Jeon, T. Y.;Kim, C. K.;Lee, J. H.
目的：研究动态增强MRI（DCE-MRI）和弥散加权MRI（DWI）在肾细胞癌（RCC）异种移植模型中监测索拉非尼早期治疗反应的可行性。方法：将索拉非尼（40 mg kg（-1））经口给予荷人RCC ACHN异种移植皮下肿瘤的BALB/c裸鼠（n = 9）。分别于治疗后0、1、3、7 d行DCE-MRI和DWI检查，计算DCE-MRI参数（K-transs和v（e））和表观弥散系数（ADC）值。肿瘤大小和体积的变化与治疗后DCE-MRI参数或ADC值的变化相关。结果：治疗后，K-transs随时间显著下降（p = 0.005），而v（e）在时间点之间没有表现出显著变化（p = 0.97）。ADC值显示随时间进行性增加（p = 0.004）。与治疗前相比，治疗3天后K-transs显示出显著降低（p = 0.039），7天后ADC值显著增加（p = 0.039）。肿瘤大小和体积在7天内没有显示出显著变化。肿瘤大小和体积的变化与DCE-MRI参数或ADC值的变化无关。结论：DCE-MRI和DWI可以显示索拉非尼治疗后1周内的早期生理变化。
Objective: To investigate the feasibility of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DWI) in monitoring early therapeutic response to sorafenib in renal cell carcinoma (RCC) xenograft models.Methods: Sorafenib (40 mg kg(-1)) was administered orally to BALB/c nude mice (n = 9) bearing subcutaneous tumours of human RCC ACHN xenografts. DCE-MRI and DWI were obtained 0, 1, 3 and 7 days after therapy, and DCE-MRI parameters (K-trans and v(e)) and apparent diffusion coefficient (ADC) values were calculated. Tumour size and volume changes were correlated with changes in DCE-MRI parameters or ADC values after therapy.Results: Following therapy, K-trans showed a significant decrease over time (p = 0.005), whereas v(e) did not demonstrate significant changes between time points (p = 0.97). ADC values showed a progressive increase over time (p = 0.004). Compared with pre-therapy, K-trans showed a significant decrease after 3 days of therapy (p = 0.039), and ADC values increased significantly after 7 days (p = 0.039). Tumour size and volume did not show significant changes during 7 days. Tumour size and volume changes were not associated with changes in DCE-MRI parameters or ADC values.Conclusion: DCE-MRI and DWI may show early physiological changes within 1 week after initiating sorafenib treatment on human RCC xenografts.Advances in knowledge: The quantitative parameters of DCE-MRI and DWI may offer the potential for assessing early therapeutic response to sorafenib in clinical trials.